« ليس باسمنا » – المدافعون الأفارقة عن علاج
بيان صحفي إعلان شركة جيلياد عن حصول ستة مصنعين للأدوية الجنيسة على تراخيص طوعية لإنتاج ليناكابافير – وهو عقار قابل للحقن مرتين في السنة للوقاية من فيروس نقص المناعة البشرية وعلاجه المحتمل –
“Pas en notre nom” – Réaction des défenseurs africains dutraitement du VIH à
Communiqué de presse – 4 Octobre 2024 Gilead annonce que six fabricants de génériques ont obtenu des licencesvolontaires pour produire le lenacapavir, un injectable révolutionnaire pour laprévention et le traitement potentiel du VIH,
“Not in Our Name” – African HIV Treatment Advocates React to Gilead’s Volun
Press Statement – 4 October 2024 Today’s announcement by Gilead that six generic manufacturers have been awarded voluntary licenses for the production of lenacapavir—a groundbreaking, twice-yearly injectable for HIV prevention and potential treatment—raises significant
Why the World Can’t Trust Pharmaceutical Companies to Ensure Global Access to Essen
Source : ITPC Global ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV prevention method—highlights why we cannot rely on pharmaceutical companies
HIV Community-Based Organizations are Fighting Patent Monopolies on Lenacapavir
Source : ITPC Global Despite the world’s efforts, there have been over a million new cases of HIV each year. Lenacapavir (LEN), a long-acting antiretroviral, could change the trajectory of the global HIV
